Abstracts tagged "Outcome measures"

Abstract Number: 2332 • ACR Convergence 2024
PsAID12 Thresholds Defining Disease Impact Severity in Psoriatic Arthritis Developed in an Observational Setting Showed Higher Sensitivity but Lower Specificity Than Those Developed in a Randomized Controlled Trial Setting
Clementina López Medina¹, Ana-Maria Orbai², Ennio Lubrano³, Laura Coates⁴, Uta Kiltz⁵, Ying Ying Leung⁶, PENELOPE PALOMINOS⁷, Juan Cañete⁸, Rossana Scrivo⁹, Andra Balanescu¹⁰, Emmanuelle Dernis¹¹, Sandra Meisalu¹², Adeline Ruyssen-Witrand¹³, MArtin Soubrier¹⁴, Sibel Aydin¹⁵, Lihi Eder¹⁶, Umut Kalyoncu¹⁷, Josef Smolen¹⁸, Maarten de Wit¹⁹ and Laure Gossec²⁰, ¹Reina Sofia University Hospital, Cordoba, Spain, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Vincenzo Tiberio Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy, ⁴University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ⁶Singapore General Hospital, Singapore, Singapore, ⁷Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, ⁸Hospital Clinic an IDIBAPS, Barcelona, Spain, ⁹Sapienza Università di Roma, Rome, Italy, Roma, Italy, ¹⁰UNIVERSITY OF MEDICINE AND PHARMACY CAROL DAVILA, Bucharest, Romania, ¹¹CH LE MANS, LE MANS, Pays de la Loire, France, ¹²Physician, Tallinn, Estonia, ¹³Toulouse University Hospital, Toulouse, France, ¹⁴Gabriel-Montpied Hospital, Clermont-ferrand, France, ¹⁵University of Ottawa - Ottawa, Ottawa, ON, Canada, ¹⁶University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, ¹⁷Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ¹⁸Medical University of Vienna, Vienna, Austria, ¹⁹Stichting Tools, Patient Research Partner, Amsterdam, Netherlands, ²⁰Sorbonne Université, Paris, France
Background/Purpose: The Psoriatic Arthritis (PsA) Impact of Disease questionnaire (PsAID12) score (range 0-10) allows for the assessment of patient-important symptoms and life impact in PsA.…
Abstract Number: 0137 • ACR Convergence 2024
The Problem of Pain in Rheumatology: Sociodemographic and Disease-related Correlates of Agreement Between Structured Data Elements and Clinical Notes in Chronic Pain Documentation Practices in EHR
Tahmina Begum¹, Bhagyavalli Veeranki¹, Ogenna Chike¹ and Titilola Falasinnu², ¹Stanford School of Medicine, Stanford, ²Stanford School of Medicine, Palo Alto, CA
Background/Purpose: To create greater precision in case definitions for chronic pain in EHRs, we recently identified 15 different case definitions for chronic pain using structured…
Abstract Number: 0378 • ACR Convergence 2024
Disparate Disease Activity Outcomes Associated with Demographic Variables in Patients with Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry
Julia Harris¹, Catherine Bingham², Sheetal Vora³, Cagri Yildirim-Toruner⁴, Kerry Ferraro⁵, Erik Friedrichsen⁶, Michelle Batthish⁷, Jon Burnham⁸, Danielle Fair⁹, Suhas Ganguli¹⁰, Mileka Gilbert¹¹, Beth Gottlieb¹², Tzielan Lee¹³, Daniel Lovell¹⁴, Melissa Mannion¹⁵, Edward Oberle¹⁶, Nancy Pan¹⁷, Linda Ray¹⁸, Michael Shishov¹⁹, Mary Toth²⁰ and Esi Morgan²¹, ¹Children's Mercy Kansas City, Overland Park, KS, ²Penn State Children’s Hospital, Hershey, ³Atrium Health Levine Children's Hospital, Charlotte, NC, ⁴Baylor College of Medicine/ Texas Children's Hospital, Houston, TX, ⁵JIA parent and CHOP volunteer, Lower Gwynedd, PA, ⁶Seattle Children's Hospital, Seattle, ⁷McMaster Children's Hospital, Hamilton, ON, Canada, ⁸Children's Hospital of Philadelphia, Philadelphia, PA, ⁹Medical College of Wisconsin/Children's Wisconsin, Wauwatosa, WI, ¹⁰Hackensack University Medical Center, Hackensack, ¹¹Medical University of South Carolina, Charleston, SC, ¹²Cohen Children's Medical Center, Lake Success, NY, ¹³Stanford University School of Medicine, Palo Alto, CA, ¹⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁵University of Alabama at Birmingham, Birmingham, AL, ¹⁶Nationwide Children's Hospital, Columbus, OH, ¹⁷Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ¹⁸University of Mississippi Medical Center, Jackson, MS, ¹⁹Phoenix Children's Hospital, Phoenix, AZ, ²⁰Nemours Foundation, Orlando, FL, ²¹Seattle Children's Hospital, Seattle, WA
Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a North American learning health network focused on improving outcomes in patients with juvenile…
Abstract Number: 0599 • ACR Convergence 2024
Sex- related Differences in Efficacy of Biologics in Axial Spondyloarthritis: A Systematic Review and Meta-analysis
Haseeb Chaudhary¹, Omer Pamuk², Sarah Abi Doumeth³, Ansaam Daoud⁴, Muhammad Shamim⁵ and Marina Magrey⁶, ¹Case Western Reserve University, Westlake, OH, ²University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ³Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland Heights, OH, ⁴Case Western Reserve University/University Hospitals, Akron, OH, ⁵University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, ⁶Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH
Background/Purpose: There is limited information about sex-related differences in efficacy of biologics in axial spondyloarthritis (axSpA). We hypothesized that females with axSpA are less likely…
Abstract Number: 0722 • ACR Convergence 2024
Factors Associated with Relapses and Performance of the French Vasculitis Study Group Relapse Score in a Cohort of Mexican Patients with ANCA-Associated Vasculitis
Andrea Hinojosa-Azaola¹, Marlon Sandino-Bermúdez², Ana Sarahí Mulia-Soto³, Juan M. Mejía-Vilet⁴ and Eduardo Martin Nares⁵, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Distrito Federal, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Ciudad de México, Mexico, ⁴Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ⁵Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Anti-neutrophil cytoplasm antibody-associated vasculitis (AAV) encompass a group of systemic inflammatory diseases with multi-organ involvement. Relapses occur in 14-44% of patients within 18-36 months…
Abstract Number: 1045 • ACR Convergence 2024
Impact of Stable Rheumatologic Therapy on Outcomes of Depression in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Jean Park¹, Cliff Rutter², Elisea Avalos-Reyes³, Mary Anderson⁴, Will Cavers⁵, Dorothea Verbrugge⁶ and Kjel Johnson⁷, ¹CVS Health, Hartford, CT, ²CVS Health, Fair Oaks Ranch, TX, ³CVS Health, Highland Village, TX, ⁴CVS Health, Irving, TX, ⁵CVS Health, Palm Beach Gardens, ⁶CVS Health, Salt Lake City, ⁷CVS Health, Tampa
Background/Purpose: Rheumatic diseases, such as rheumatoid arthritis (RA), psoriatic arthritis (PA), and systemic lupus erythematosus (SLE) can significantly impact quality of life. This burden extends…
Abstract Number: 1394 • ACR Convergence 2024
Nationwide Retrospective Cohort Study on Clinical Outcomes in Rheumatoid Arthritis Patients Treated with JAK Inhibitors
Yurilu Gonzalez Moret¹, Diego Lema² and Fabian Rodriguez Quinonez³, ¹Jefferson Einstein Hospital, Philadelphia, PA, ²Universidad Central de Venezuela, University of Wisconsin, Philadelphia, PA, ³Einstein Medical Center Philadelphia, Philadelphia, PA
Background/Purpose: Janus kinase inhibitors (JAKi) are a class of disease activity-modifying drugs (DMARDs) that have quickly established a role in managing rheumatoid arthritis. Inhibition of…
Abstract Number: 1597 • ACR Convergence 2024
Baseline Glucocorticoid-Related Toxicity in Newly-Diagnosed and Relapsing ANCA-Associated Vasculitis
Naomi Patel¹, Sarah Bray², Darcy Trimpe³, David Jayne⁴, Peter Merkel⁵ and John Stone⁶, ¹Massachusetts General Hospital, Boston, MA, ²Amgen Ltd, Cambridge, United Kingdom, ³Amgen Inc., Thousand Oaks, CA, ⁴University of Cambridge, Cambridge, United Kingdom, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Massachusetts General Hospital , Harvard Medical School, Concord, MA
Background/Purpose: The ADVOCATE trial evaluated avacopan (a C5a receptor antagonist) as a replacement for a standard prednisone taper in the treatment of granulomatosis with polyangiitis…
Abstract Number: 2143 • ACR Convergence 2024
Analysis of Effectiveness and Safety of Romosozumab in Patients with Very High Risk of Fracture in a Spanish Population
Marina soledad Moreno Garcia¹, Roxana González Mazario², yedra uson Rodriguez³, Erardo meriño Ibarra⁴, Emilio Giner⁵, Juan Carlos Cobeta García⁶, Marilia Arce Benavente⁷, maria Dolores Fábregas canales⁸, Julia Ullier Bellmunt³, Giuliano Boselli³, pilar martinez Valles⁷, Jorge Juan Fragío Gil⁹, carlos Vazquez Galeano⁷ and Ana Turrion Nieves¹⁰, ¹hospital Miguel Servet . Zaragoza, Zaragoza, Aragon, Spain, ²Hospital General de Valencia, Valencia, Comunidad Valenciana, Spain, ³hospital miguel servet, zaragoza, Aragon, Spain, ⁴Hospital San Jorge Huesca, zaragoza, ⁵Hospital Royo Villanova, Teruel, Spain, ⁶Hospital Ernest Lluch, zaragoza, ⁷hospital miguel servet, Zaragoza, ⁸Hospital de Barbastro, Huesca, Spain, ⁹Hospital General Universitario, Valencia, Comunidad Valenciana, Spain, ¹⁰Rheumatology Department, Hospital Universitario Virgen de la Vega, Salamanca, Spain
Background/Purpose: Excluding clinical trials, there is limited evidence on the effect of 12 months of romosozumab treatment on increasing bone mineral density (BMD) in real-world…
Abstract Number: 2366 • ACR Convergence 2024
Improvement in Pain-Associated Biomarkers with Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with PsA in a Double-Blind Phase 2 Study (IM011-084)
Philip Mease¹, Christopher Ritchlin², Lu Gao³, Peter Schafer⁴, Miroslawa Nowak³, Ian M. Catlett³ and Jinqi Liu³, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ³Bristol Myers Squibb, Princeton, NJ, ⁴Bristol Myers Squibb, BELLE MEAD, NJ
Background/Purpose: Pain is a core domain of PsA, and reduction of pain is a primary treatment concern for patients with PsA. Pain has been reported…
Abstract Number: 0149 • ACR Convergence 2024
Beliefs on Self-Management in Rheumatoid Arthritis Compared to Other Chronic Diseases Using the Nationally Representative Medical Expenditure Panel Survey
Samuel Good¹, Bryant England² and Elizabeth Volkmann³, ¹University of California, Los Angeles, Los Angeles, CA, ²University of Nebraska Medical Center, Omaha, NE, ³University of California, Department of Medicine, Los Angeles, CA, USA, Los Angeles
Background/Purpose: Studies that evaluate experiences of living with rheumatoid arthritis (RA) have found that patients identify self-empowerment and a sense of control as important factors…
Abstract Number: 0385 • ACR Convergence 2024
Cross-cultural Validation of the “Effects of Youngsters-Eyesight on Quality of Life (EYE-Q)”: A Measure of Vision-related Quality of Life and Function in Childhood Uveitis
sheila Angeles-Han¹, Jordi Anton², Amra Adrovic³, Patricia Costa Reis⁴, Joke De Boer⁵, Séverine Guillaume-Czitrom⁶, Theresa Hennard⁷, Marija Jelusic⁸, Ozgur Kasapcopur⁹, Ilaria Maccora¹⁰, Hana Malcova¹¹, Joseph McDonald¹², Najima Mwase¹³, Gabriele Simonini¹⁴, Waheba Slamang¹⁵, Derrik du Toit¹⁶, Hendrike van Vollenhoven¹⁶ and Ivan Foeldvari¹⁷, ¹Cincinnati Children's Hospital, Cincinnati, OH, ²Hospital Sant Joan de Déu. Universitat de Barcelona, Esplugues de Llobregat (Barcelona), Spain, ³Deparment of Pediatric Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey, ⁴Hospital de Santa Maria, Lisbon, Portugal, ⁵Department of ophthalmology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶University Hospital of Bicetre, Kremlin-Bicêtre, France, ⁷Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁸University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, ⁹Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ¹⁰?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, ¹¹FN Motol, Praha, Czech Republic, ¹²University of Chicago, Chicago, IL, ¹³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁴Meyer Children Hospital IRCCS; NEUROFARBA Department, University of Florence, Florence, Italy, ¹⁵University of Cape Town, Department of Child and Adolescent Health, Cape Town, South Africa, ¹⁶Red Cross Children’s Hospital, Cape Town, South Africa, ¹⁷Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Childhood uveitis leads to sight-threatening complications in 50% of affected children and significantly impacts a child’s quality of life and function. The Multinational Interdisciplinary…
Abstract Number: 0615 • ACR Convergence 2024
Socioeconomic Determinants of Lupus Hospitalization Outcomes: A Review of Current Knowledge and Analysis of the 2016-2019 NRD Database
Akhila Arya P V¹, Madhumitha Rondla², Jai Juganya Tirupur Ponnusamy³ and Dileep C Unnikrishnan⁴, ¹Bridgeport Hospital, Stratford, CT, ²Texas tech university health sciences center, El paso, El Paso, TX, ³Metrowest Medical Center, Framingham, ⁴Bridgeport Hospital, Bridgeport, CT
Background/Purpose: Hospitalizations due to systemic lupus erythematosus (SLE) often stem from lupus flares and infections. Socioeconomic factors influencing outcomes in SLE hospitalizations have been studied…
Abstract Number: 0733 • ACR Convergence 2024
Inpatient Outcomes in ANCA-Associated Vasculitis: An In-Depth Cross-Sectional Analysis Using NIS Data (2016-2020)
Sai Shanmukha Sreeram Pannala¹, fares Saliba², Medha Rajamanuri³ and Veena Katikineni⁴, ¹Staten Island University Hospital, Northwell Health, staten island, new york city, NY, ²Staten Island University Hospital, Staten Island, NY, ³Southern Illinois University School of Medicine, Springfield, IL, ⁴Providence, Victorville, CA
Background/Purpose: Antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are a heterogeneous group of rare autoimmune conditions characterized by inflammation of blood vessels, leading to various clinical…
Abstract Number: 1047 • ACR Convergence 2024
Impact of Treatment Switching on Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, or Systemic Lupus Erythematosus
Jean Park¹, Cliff Rutter², Elisea Avalos-Reyes³, Mary Anderson⁴, Will Cavers⁵, Dorothea Verbrugge⁶ and Kjel Johnson⁷, ¹CVS Health, Hartford, CT, ²CVS Health, Fair Oaks Ranch, TX, ³CVS Health, Highland Village, TX, ⁴CVS Health, Irving, TX, ⁵CVS Health, Palm Beach Gardens, ⁶CVS Health, Salt Lake City, ⁷CVS Health, Tampa
Background/Purpose: Switching treatment from conventional to biologic disease-modifying antirheumatic drugs (DMARDs) is a common practice for managing autoimmune diseases such as rheumatoid arthritis (RA), psoriatic…

« Previous Page
1
…
5
6
7
8
9
…
49
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].